Home > About Us > Press Release > News
Daewoong Pharmaceutical attended ICAD 2018 and promoted benefit of Nabota | |||
Date | 2018-11-27 | Hit | 802 |
---|---|---|---|
Daewoong Pharmaceutical attended ICAD 2018 and promoted benefit of Nabota - Presented clinical result from US, EU and Canada and recent Nabota regimens On Nov. 27, Daewoong Pharmaceutical (CEO Sengho Jeon) announced that it attended ICAD 2018 from Nov. 23 to 24 in Bangkok, Thailand and presented outstanding clinical result of Nabota and its various regimens. ICAD is held annually in Thailand and is one of most esteemed international cosmetic surgery symposium. Over 1,200 persons involved in aesthetics and cosmetic surgery from 60 countries participated in the 12th anniversary of this event. Daewoong Pharmaceutical had its own booth and symposium to proactively promote the benefits of Nabota(Jeuveau). Dr. Mart Maiprasert, Thai dermatologist, was the senior person at the symposium and Dr. Cristina Puyat, Filipino dermatologist, Dr. Yunjin Choi, Korean dermatologist at Yonsei BB Skin Clinic, were speakers at the event, where they presented the result of clinical study that involved over 2,000 subjects in the US, Europe and Canada. The interests of the participants were the highest when the most recent regimens using Nabota was shared with the group. Dr. Puyat said, “Nabota is a highly pure product with over 98% 900Kda protein, a substance of all type A botulinum toxins known to be most stable and effective. It is fast and long-lasting, and its efficacy and safety have been substantiated through clinical studies in Korea and other advanced countries.” In addition to the symposium, Daewoong Pharmaceutical also held NABOTA Aesthetic Forum in Bangkok, on Nov. 24, a parallel program for doctors in Asian countries where Nabota is marketed. Attendees included 20 or so Korean and Thai doctors, including Dr. Hyeongseok Ko of Samsung Lohas Clinic, Dr. Awika Rongthong of Awika Clinic, where they had a valuable time sharing their experience and suggestions using Nabota. Seongsu Park, head of Nabota Business HQ, said, “We plan to solidify the foundation of Nabota in the Asian markets as well as global markets by proactively promoting the outstanding results of the most recent clinical studies of Nabota through international symposiums and networks.” # # #
[Photo 1] Daewoong Pharmaceutical attended ICAD 2018 from Nov. 23 to 24 in Bangkok, Thailand and presented outstanding clinical result of Nabota and its various regimens. [Photo 2] Dr. Cristina Puyat, Filipino dermatologist and the speaker at ICAD 2018, is presenting the result of clinical study on Nabota and wrinkles between eyebrows conducted in the US, Europe and Canada |